Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are older than 6 months of age
- People who have a B cell blood cancer that has come back after previously receiving a type of treatment that targets a protein called CD19
- People whose cancer cells carry at least one of the following markers on their surface: CD22, CD123, CD38, CD10, or CD20
- People who have a general health score above 80 (on a standard scale doctors use to measure how well someone is functioning day-to-day) and are expected to live longer than one month
- People whose haemoglobin (a measure of red blood cells in the blood) is above 80 g/L
- People who have no medical reasons preventing the collection of blood cells
Who may not be able to join:
- People who have other serious active illnesses that would make it difficult for doctors to measure how well the treatment is working
- People who have a bacterial, fungal, or viral infection that cannot be controlled
- People who are living with HIV
- People who have an active hepatitis B (HBV) or hepatitis C (HCV) infection
- People who are pregnant or currently breastfeeding
- People who have been taking steroid medications throughout the whole body (such as tablets or injections, not creams) within one week before treatment
- People who, in the doctors' judgement, would have difficulty participating in ongoing assessments and follow-up visits (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 0755-86573763
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety of fourth generation anti-CD22/CD123/CD38/CD10/CD20 CAR-T cells
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.